A Single-center, Randomized, Double-blind, Placebo-controlled, Dose Escalation Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PG-033 by Single Dose Administration and Food Effect in Healthy Volunteers
Latest Information Update: 13 Jun 2025
At a glance
- Drugs PG 033 (Primary)
- Indications Neuralgia
- Focus Adverse reactions
- Sponsors Prime Gene Therapeutics
Most Recent Events
- 13 Jun 2025 New trial record